Randomized phase II study comparing two doses of regorafenib in second-line treatment for advanced hepatocellular carcinoma

Background & Aims: The RESORCE trial confirmed regorafenib as a second-line treatment for advanced hepatocellular carcinoma (HCC) in patients who tolerated sorafenib. However, its safety and efficacy in patients with diverse treatment histories remain unknown. The REGAIN study sought to assess r...

Полное описание

Библиографические подробности

Главные авторы:	Keisuke Koroki, Sadahisa Ogasawara, Sae Yumita, Miyuki Nakagawa, Hiroaki Kanzaki, Kazufumi Kobayashi, Masanori Inoue, Masato Nakamura, Naoya Kanogawa, Takayuki Kondo, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Yuki Shiko, Yoshihito Ozawa, Yosuke Inaba
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2025-10-01
Серии:	JHEP Reports
Предметы:	Hepatocellular carcinoma Regorafenib RESORCE trial Randomized controlled trial
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2589555925001879
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!